FundaMental Pharma GmbH (“FundaMental”), a preclinical neuroscience company spun out of Heidelberg University.

Built on the pioneering research of Professor Hilmar Bading and Dr. Jing Yan published in Science[1], the founders of FundaMental have identified first-in-class small molecule inhibitors for treatment of a range of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) and Huntington’s Disease. FundaMental’s novel approach relies on separating the normal neuroprotective effect of synaptic glutamate from its neurotoxic extra-synaptic actions, which are eliminated by the inhibitors.

[1]: source